AEMD Aethlon Medical to Present at SeeThruEquity I
Post# of 94143
Posted On: 11/07/2013 10:21:36 AM
AEMD Aethlon Medical to Present at SeeThruEquity Investor Conference
SAN DIEGO, Nov. 7, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Company Chairman and CEO, Jim Joyce will present a corporate overview at the SeeThruEquity Investor Conference on November 12th at 10:30 am Eastern Standard Time (EST). Mr. Joyce's presentation will be webcast via the following link: http://wsw.com/webcast/seethru5/AEMD. The conference will be held at Convene Midtown East (730 Third Avenue), New York City. Additional details can be accessed online at: www.seethruequity.com
(Logo: http://photos.prnewswire.com/prnh/20130912/LA78266LOGO)
(Logo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)
Aethlon is currently preparing to launch the first U.S. studies of Hemopurifier® therapy based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA) to initiate feasibility studies in Hepatitis C (HCV) infected individuals.
On the evening of November 12th, Mr. Joyce will also co-host a grand opening event for the Company's Exosome Sciences, Inc. (ESI) subsidiary at 6:30pm EST. Individuals that wish to attend the event should RSVP by email to Chris Wetzel (ESI Director of Operations) by the end of the business day on Friday November 8th. Chris's email address is: cwetzel@exosomesciences.com. The event will be held at the recently established ESI lab located within the Princeton Research Center. The address is 11 Deer Park Drive, Suite 103, Monmouth Junction, NJ 08852. Directions can be accessed online at: www.princetoncorporateplaza.com/contact.html.
About Aethlon Medical
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
SOURCE Aethlon Medical, Inc.
Copyright 2013 PR Newswire
SAN DIEGO, Nov. 7, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), announced today that Company Chairman and CEO, Jim Joyce will present a corporate overview at the SeeThruEquity Investor Conference on November 12th at 10:30 am Eastern Standard Time (EST). Mr. Joyce's presentation will be webcast via the following link: http://wsw.com/webcast/seethru5/AEMD. The conference will be held at Convene Midtown East (730 Third Avenue), New York City. Additional details can be accessed online at: www.seethruequity.com
(Logo: http://photos.prnewswire.com/prnh/20130912/LA78266LOGO)
(Logo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)
Aethlon is currently preparing to launch the first U.S. studies of Hemopurifier® therapy based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA) to initiate feasibility studies in Hepatitis C (HCV) infected individuals.
On the evening of November 12th, Mr. Joyce will also co-host a grand opening event for the Company's Exosome Sciences, Inc. (ESI) subsidiary at 6:30pm EST. Individuals that wish to attend the event should RSVP by email to Chris Wetzel (ESI Director of Operations) by the end of the business day on Friday November 8th. Chris's email address is: cwetzel@exosomesciences.com. The event will be held at the recently established ESI lab located within the Princeton Research Center. The address is 11 Deer Park Drive, Suite 103, Monmouth Junction, NJ 08852. Directions can be accessed online at: www.princetoncorporateplaza.com/contact.html.
About Aethlon Medical
Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
SOURCE Aethlon Medical, Inc.
Copyright 2013 PR Newswire
(0)
(0)Scroll down for more posts ▼